Lake Forest, CA, February 17, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced the launch of a new logistics service supporting complete facility relocation of critical cryogenically frozen sample collections.
Cryoport is providing complete logistics management for the relocation of a leading research laboratory and IVF clinic, with all material shipping and transport supervised and performed by trained personnel under compliance with DOT, CDC and IATA regulations.
The relocation of a laboratory or clinic is a significant and complex endeavor consisting of valuable and irreplaceable research samples such as cell lines, DNA, and other biological samples such as an individual’s reproductive material critical for family creation. The critical nature of these samples requires full regulatory knowledge under an umbrella of exact environmental conditions for the transfer. Cryoport has the best-in-class logistics solutions and possesses the expertise in handling to safely and successfully relocate cryogenically frozen samples without error.
Jerrell Shelton, Cryoport’s CEO, stated, “We are uniquely suited to support the wholesale movement of critical laboratory samples that require strict conditions from one location to another in a controlled manner. The fact that institutions and clinics trust their entire life’s work to our care is a testament to our validated cryogenic logistics solutions paired with our experience and knowledge in supporting such relocations. We look forward to further collaboration with leading research centers and other organizations in their relocation over the coming months.”
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.Investor Contacts:Todd Fromer / Garth Russelltfromer@kcsa.com / email@example.comP: 1 212-682-6300